SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (1952)4/9/2003 10:21:55 AM
From: scaram(o)uche  Read Replies (1) of 2243
 
In general..... from the veteran biotech investor's perspective..... one looks past AACR to ASCO. I've never traded AACR.

In the old days, virtually every abstract submitted to AACR was published. There was no peer review. Presentations are, and always have been, a different issue. But.... it's sort of like ASM versus ICAAC...... one meeting moves stocks, the other doesn't.

But, in the day of "popcorn" and roving bands of traders who are looking to find suckers to take the potential downside of their momentary trades? You're correct to watch closely.

If you have really primo data, you'll generally aim for ASCO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News